NCT02042222View on ClinicalTrials.gov

Novel Dose Escalation to Predict Treatment With Hydroxyurea

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Sickle Cell Disease
Interventions
DRUG

Hydroxyurea

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

Baylor College of Medicine

OTHER

NCT02042222 - Novel Dose Escalation to Predict Treatment With Hydroxyurea | Biotech Hunter | Biotech Hunter